Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

NCT01987908 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
35
Enrollment
INDUSTRY
Sponsor class

Stopped Study was terminated early by the Sponsor due to unblinding between study drug and placebo groups at the subject, site and Sponsor levels.

Conditions

Interventions

Sponsor

Baxalta now part of Shire